A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs VLX 600 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Vivolux
- 26 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 26 Apr 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2017.
- 20 Aug 2014 Status changed from not yet recruiting to recruiting, as per Mayo Clinic record.